Theratechnologies Inc T.TH

AACR abstracts

[scarlet1967]

For those who are interested from previous AACR presentations.

https://cancerres.aacrjournals.org/content/80/16_Supplement/2910

 

Abstract 1061: Increasing potency of anticancer drugs through Sortilin receptor-mediated cancer therapy: A new targeted approach for the treatment of ovarian cancer | Cancer Research

 

[jfm1330]

Something Thera did not talk a lot about to my knowledge, maybe I missed it, is the level of Sortilin receptors expression in healthy cells. This is important because their peptide-drug conjugate will also concentrate the cytotoxic drug in healthy cells bearing Sortilin receptors. I know that for Lutathera clear overexpression of Somatostatin on cancer cells is the key to efficacy. You really

[realitycheck4u]

This post has been removed in accordance with Community Policy

[qwerty22]

Reality I think that this paper you highlight falls into the category of 'potential 2nd MOA' for the THTX PDC. There is another paper just out in colorectal cancer that shows a very similar role for sortilin in aggressiveness of the cancer. https://onlinelibrary.wiley.com/doi/10.1111/jcmm.15752#jcmm15752-fig-0002 But this is speculative for now because the company would first need to

[realitycheck4u]

This post has been removed in accordance with Community Policy

[qwerty22]

These are the likely cancers for the basket trial which could easily start as soon as they get proof of efficacy in the lead indication (if that comes)

[qwerty22]

There are many targeted drug programs that go thru this process without a nucleotide imaging tool, many fail, some look promising, so far a small number have got approved. The one u are referring is mostly the exception rather than the rule. Those programs initiate with all the similar uncertainties that you list, for the most part you simple have to accept them and understand those uncertainties